RPHM
Price:
$18.2
Market Cap:
$60.84M
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.[Read more]
Industry
Biotechnology
IPO Date
2021-04-08
Stock Exchange
NASDAQ
Ticker
RPHM
According to Reneo Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 25.69M. This represents a change of -97.50% compared to the average of 1.03B of the last 4 quarters.
The mean historical Enterprise Value of Reneo Pharmaceuticals, Inc. over the last ten years is 424.76M. The current 25.69M Enterprise Value has changed 504.89% with respect to the historical average. Over the past ten years (40 quarters), RPHM's Enterprise Value was at its highest in in the September 2023 quarter at 2.56B. The Enterprise Value was at its lowest in in the September 2001 quarter at 0.
Average
424.76M
Median
273.62M
Minimum
0
Maximum
1.43B
Discovering the peaks and valleys of Reneo Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = Infinity%
Maximum Annual Enterprise Value = 1.43B
Minimum Annual Increase = -95.94%
Minimum Annual Enterprise Value = 0
Year | Enterprise Value | Change |
---|---|---|
2023 | 22.41M | -95.94% |
2022 | 552.30M | -61.29% |
2021 | 1.43B | 254.64% |
2020 | 402.27M | 177.47% |
2019 | 144.98M | Infinity% |
The current Enterprise Value of Reneo Pharmaceuticals, Inc. (RPHM) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
667.11M
5-year avg
509.71M
10-year avg
424.76M
Reneo Pharmaceuticals, Inc.’s Enterprise Value is less than Prime Medicine, Inc. (461.31M), less than Ginkgo Bioworks Holdings, Inc. (143.59M), less than Ocean Biomedical, Inc. (42.20M), less than Royalty Pharma plc (18.03B), greater than Immix Biopharma, Inc. (20.49M), greater than CNS Pharmaceuticals, Inc. (2.61M), greater than Hepion Pharmaceuticals, Inc. (1.72M), greater than Freeline Therapeutics Holdings plc (2.82M), greater than AVROBIO, Inc. (-85302404.00), less than Summit Therapeutics Inc. (14.64B), less than Nkarta, Inc. (193.08M), less than Cullinan Oncology, Inc. (810.70M), less than Kezar Life Sciences, Inc. (41.06M), greater than Kronos Bio, Inc. (14.20M), less than Adaptive Biotechnologies Corporation (942.14M), less than Legend Biotech Corporation (8.13B), less than Vir Biotechnology, Inc. (1.02B), less than Apellis Pharmaceuticals, Inc. (3.59B), greater than Werewolf Therapeutics, Inc. (139.97K), less than Edgewise Therapeutics, Inc. (3.19B), less than Decibel Therapeutics, Inc. (96.42M), less than Celcuity Inc. (634.84M), less than C4 Therapeutics, Inc. (462.75M),
Company | Enterprise Value | Market cap |
---|---|---|
461.31M | $475.32M | |
143.59M | $424.04M | |
42.20M | $31.18M | |
18.03B | $12.19B | |
20.49M | $43.37M | |
2.61M | $3.98M | |
1.72M | $3.68M | |
2.82M | $28.28M | |
-85302404.00 | $5.24M | |
14.64B | $14.71B | |
193.08M | $227.90M | |
810.70M | $922.99M | |
41.06M | $51.73M | |
14.20M | $57.28M | |
942.14M | $775.70M | |
8.13B | $7.99B | |
1.02B | $1.28B | |
3.59B | $3.48B | |
139.97K | $98.77M | |
3.19B | $3.23B | |
96.42M | $123.37M | |
634.84M | $568.78M | |
462.75M | $455.30M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Reneo Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Reneo Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Reneo Pharmaceuticals, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Reneo Pharmaceuticals, Inc. (RPHM)?
What is the 3-year average Enterprise Value for Reneo Pharmaceuticals, Inc. (RPHM)?
What is the 5-year average Enterprise Value for Reneo Pharmaceuticals, Inc. (RPHM)?
How does the current Enterprise Value for Reneo Pharmaceuticals, Inc. (RPHM) compare to its historical average?